Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2026-03-14
Target enrollment:
Participant gender:
Summary
This phase I trial tests the safety, side effects, and best dose of camu camu when used in
combination with nivolumab and ipilimumab in treating patients with kidney cancer that has
spread to other places in the body. A monoclonal antibody is a type of protein that can bind
to certain targets in the body, such as molecules that cause the body to make an immune
response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab and
ipilimumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Camu camu is a prebiotic that may have a
beneficial effect on the immune system. Giving camu camu in combination with nivolumab and
ipilimumab may kill more tumor cells than nivolumab and ipilimumab alone in patients with
metastatic kidney cancer.